论文部分内容阅读
目的:研究乳腺癌组织中原癌基因HER-2的表达与病理学特征和肿瘤新生血管生成的关系。方法:应用免疫组织化学方法检测62例浸润性导管癌,5例单纯导管原位癌及13例导管原位癌局灶浸润组织中HER-2和血管内皮生长因子(VEGF)的表达,同时应用CD34单抗标记检测肿瘤微血管密度(MVD)。结果:37.5%(30/80)乳腺癌组织中存在HER-2阳性表达。HER-2表达与淋巴结转移、临床分期、组织学分级以及雌孕激素受体相关(χ2值分别为8.087、8.532、10.146、19.750和4.391,P值均<0.05);HER-2和VEGF表达及MVD明显相关。结论:HER-2表达与乳腺癌发生、发展及血管生成密切相关;新生血管生成可能是HER-2致癌机制之一。
OBJECTIVE: To study the relationship between the expression of HER-2 and the pathological features and tumor neovascularization in breast cancer. Methods: Immunohistochemistry was used to detect the expression of HER-2 and VEGF in 62 invasive ductal carcinomas, 5 simple ductal carcinoma in situ and 13 cases of invasive ductal carcinoma in situ. At the same time, CD34 monoclonal antibody was used to detect tumor microvessel density (MVD). Results: The positive expression of HER-2 existed in 37.5% (30/80) of breast cancer tissues. The expression of HER-2 was correlated with lymph node metastasis, clinical stage, histological grade and estrogen-progesterone receptor (χ2 = 8.087, 8.532, 10.146, 19.750 and 4.391 respectively, P < MVD is obviously related. Conclusion: The expression of HER-2 is closely related to the occurrence, development and angiogenesis of breast cancer. The neovascularization may be one of the mechanisms of carcinogenesis of HER-2.